跳到正文
原文
STAT 主站· Elaine Chen·· 7 天前AI 评分30

Oura 收购 Counsel Health 引发专家对 Eli Lilly 利益冲突的质疑

STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say

AI 导读

本周 Oura 宣布收购远程医疗公司 Counsel Health,该议题引发专家对 Eli Lilly 利益冲突的质疑。Eli Lilly 已将 Counsel Health 列入其 GLP-1 处方的推荐提供商名单,而 Counsel 的医生将能访问 Oura 智能戒指收集的用户数据以协助诊疗。药企日益推广与其有关联的远程医疗公司进行 GLP-1 处方开立的模式正受到审查。

正文

Intertwined relationships between drugmakers, telemedicine companies draw scrutiny

Emilie Megnien/AP

By Elaine Chen

Nov. 13, 2026

Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Pharma companies that make GLP-1 drugs have increasingly promoted telehealth companies that prescribe the popular treatments. With a new deal announced this week, one of those relationships is expected to grow more complicated.

Eli Lilly has been featuring a telehealth company called Counsel Health on a list of providers for patients seeking a GLP-1 prescription.

On Tuesday, Counsel said it would be acquired by the smart ring maker Oura, allowing Counsel clinicians access to the data gathered through the ring so they can help customers understand the data and then diagnose or treat any conditions.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. National Biotech Reporter

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

来源:STAT 主站 · statnews.com